Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Medicines & Healthy Lifestyle

FDA to Review Resubmitted Application for Severe Burn Therapy NexoBrid

admin by admin
August 3, 2022
in Medicines & Healthy Lifestyle


The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for NexoBrid® for eschar removal (debridement) in adults with deep partial thickness and/or full thickness thermal burns.

NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The product selectively removes burn eschar within 4 hours without harming surrounding viable tissue.

The resubmitted BLA comes after the FDA issued a Complete Response Letter to MediWound in June 2021 requiring additional manufacturing data. The application is supported by the phase 3 DETECT trial (ClinicalTrials.gov Identifier: NCT02148705), which compared NexoBrid to gel vehicle placebo or standard of care in adult patients with deep partial and full thickness thermal burns up to 30% of total body surface area (N=175). 


Continue Reading

Findings from the trial showed that NexoBrid was associated with a higher incidence of complete eschar removal, a shorter time to complete eschar removal, a lower incidence of surgical eschar removal, and reduced blood loss during the eschar removal procedure, compared with standard of care.

“We are thrilled to have our application accepted and to be one step closer to commercializing NexoBrid in the US,” said Ofer Gonen, CEO of MediWound. “We have seen NexoBrid help burn patients worldwide and knowing that it may be soon available in the United States is very gratifying.”

NexoBrid is currently approved in the European Union and other international markets. The FDA is expected to make a decision on the application on January 1, 2023.

Reference

MediWound announces US FDA acceptance of Biologics License Application for NexoBrid for the treatment of severe thermal burns. News release. MediWound Ltd. Accessed August 3, 2022. https://www.globenewswire.com/news-release/2022/08/03/2491251/30505/en/MediWound-Announces-U-S-FDA-Acceptance-of-Biologics-License-Application-for-NexoBrid-for-the-Treatment-of-Severe-Thermal-Burns.html

This article originally appeared on MPR

Topics:

Burns
Dermatological Disorders



Source link

Previous Post

Why Exercise Doesn’t Help People With Long COVID

Next Post

Monoclonal antibody treatment for malaria shows encouraging results

Next Post

Monoclonal antibody treatment for malaria shows encouraging results

Recommended

The Gut-Brain Connection: Understanding GI Symptoms in Autism Spectrum Disorders

August 1, 2022

Climate Changes are Making Some Bird Feathers Less Colorful

July 24, 2022

Don't miss it

Pharmaceutical

Health Bulletin 18/August/2022

August 18, 2022
Medicines & Healthy Lifestyle

FDA Approves Citrate-Free, High Concentration of Hadlima

August 18, 2022
Medicines & Healthy Lifestyle

Use Of Sleep Medications Among Americans Declining In Recent Years

August 18, 2022
News

Fake Positive Reviews; Low Quality Guidelines; and CDC Reorg

August 18, 2022
Pharmaceutical

Organ transplantation is at a crossroads. Major reform is needed

August 18, 2022
News

Do Wind Instruments Spread COVID?

August 18, 2022

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.